Compounds, compositions, and methods for the treatment of cancers
The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.
1. A method of inhibiting proliferation of a cell, wherein the cell is a cancer cell selected from the group consisting of a lung cancer cell and a colorectal cancer cell, comprising contacting the cell with an effective amount of a compound of selected from the group consisting of
2. The method of claim 1 , wherein the compound induces cell death of the cancer cell.
3. The method of claim 1 , wherein the platinum level in the cell is increased.
4. The method of claim 1 , wherein the compound is dosed as a nanoparticle.
5. The method of claim 4 , wherein the nanoparticle comprises polyester.
6. The method of claim 5 , where the polyester is selected from polycaprolactone, poly(p-dioxanone), poly(butylene succinate), polycarbonate, polylactide, polyglycolide, or poly(lactide-co-glycolide).
7. The method of claim 6 , wherein the polyester is selected from polylactide, polyglycolide, or poly(lactide-co-glycolide).
8. The method of claim 7 , wherein the polylactide, polyglycolide, or poly(lactide-co-glycolide) has a number weight molecular weight of about 15 kDa to about 200 kDa.
9. The method of claim 4 , wherein the nanoparticle comprises a PEGylated polylactide, a PEGylated polyglycolide, or a PEGylated poly(lactide-co-polyglycolide.
10. The method of claim 9 , wherein the PEG unit in the PEGylated polylactide, PEGylated polyglycolide, or PEGylated poly(lactide-co-polyglycolide has a number average molecular weight from about 1 kDa to 25 kDa.
11. The method of claim 4 , wherein the nanoparticle has an average particle size between about 20 nm and about 220 nm.
12. The method of claim 4 , wherein the nanoparticle is formulated in sucrose.
13. The method of claim 4 , wherein less than 50% of the compound is released in the first hour.
14. The method of claim 4 , wherein the compound is released in the course of 48 hours.
15. The method of claim 1 , wherein the compound is dosed as a free compound.
16. The method of claim 15 , wherein the free compound is formulated with a surfactant.
17. The method of claim 15 , wherein the free compound is formulated with a lyoprotectant.
18. The method of claim 15 , wherein the free compound is formulated with sucrose, or physiological saline.
19. A method of treating cancer in a subject, wherein the cancer is selected from the group consisting of lung cancer and colorectal cancer, the method comprising administering to the subject an effective amount of a compound of a compound of selected from the group consisting of